Primary ependymoma of the ovary, in which long-term oral etoposide (VP-16) was effective in prolonging disease-free survival

Mikio Mikami, Yuuki Komuro, Naoko Sakaiya, Chisei Tei, Takashi Kurahashi, Shinichi Komiyama, Takanori Hirose

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background. Ovarian ependymoma is an extremely unusual teratoma of the ovary with only eight cases previously reported in the literature worldwide. Case. A 26-year-old woman presented in 1992 with a sensation of abdominal fullness. The laparotomy revealed ovarian cancer (stage III), which proved to be an ependymoma pathologically. Three courses of the PVP regimen (cisplatin, vinblastine, peplomycin) and pelvic irradiation were administered postoperatively. Oral administration of etoposide (VP-16) was initiated after the residual tumor began to proliferate, and the tumor decreased in size and never regrew during etoposide administration for a total of 5 years and 8 months. The recurrent tumor was observed soon after the drug was discontinued. Conclusion. Oral administration of etoposide was effective in prolonging disease-free survival.

Original languageEnglish
Pages (from-to)149-152
Number of pages4
JournalGynecologic Oncology
Volume83
Issue number1
DOIs
Publication statusPublished - 2001
Externally publishedYes

Fingerprint

Ependymoma
Etoposide
Disease-Free Survival
Ovary
Oral Administration
Peplomycin
Vinblastine
Teratoma
Residual Neoplasm
Ovarian Neoplasms
Laparotomy
Cisplatin
Neoplasms
Pharmaceutical Preparations

Keywords

  • Ependymoma
  • Etoposide
  • Ovarian neoplasma
  • VP-16

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Cite this

Primary ependymoma of the ovary, in which long-term oral etoposide (VP-16) was effective in prolonging disease-free survival. / Mikami, Mikio; Komuro, Yuuki; Sakaiya, Naoko; Tei, Chisei; Kurahashi, Takashi; Komiyama, Shinichi; Hirose, Takanori.

In: Gynecologic Oncology, Vol. 83, No. 1, 2001, p. 149-152.

Research output: Contribution to journalArticle

Mikami, Mikio ; Komuro, Yuuki ; Sakaiya, Naoko ; Tei, Chisei ; Kurahashi, Takashi ; Komiyama, Shinichi ; Hirose, Takanori. / Primary ependymoma of the ovary, in which long-term oral etoposide (VP-16) was effective in prolonging disease-free survival. In: Gynecologic Oncology. 2001 ; Vol. 83, No. 1. pp. 149-152.
@article{878a1c741a9c463abc62f28a9b19c05c,
title = "Primary ependymoma of the ovary, in which long-term oral etoposide (VP-16) was effective in prolonging disease-free survival",
abstract = "Background. Ovarian ependymoma is an extremely unusual teratoma of the ovary with only eight cases previously reported in the literature worldwide. Case. A 26-year-old woman presented in 1992 with a sensation of abdominal fullness. The laparotomy revealed ovarian cancer (stage III), which proved to be an ependymoma pathologically. Three courses of the PVP regimen (cisplatin, vinblastine, peplomycin) and pelvic irradiation were administered postoperatively. Oral administration of etoposide (VP-16) was initiated after the residual tumor began to proliferate, and the tumor decreased in size and never regrew during etoposide administration for a total of 5 years and 8 months. The recurrent tumor was observed soon after the drug was discontinued. Conclusion. Oral administration of etoposide was effective in prolonging disease-free survival.",
keywords = "Ependymoma, Etoposide, Ovarian neoplasma, VP-16",
author = "Mikio Mikami and Yuuki Komuro and Naoko Sakaiya and Chisei Tei and Takashi Kurahashi and Shinichi Komiyama and Takanori Hirose",
year = "2001",
doi = "10.1006/gyno.2001.6343",
language = "English",
volume = "83",
pages = "149--152",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Primary ependymoma of the ovary, in which long-term oral etoposide (VP-16) was effective in prolonging disease-free survival

AU - Mikami, Mikio

AU - Komuro, Yuuki

AU - Sakaiya, Naoko

AU - Tei, Chisei

AU - Kurahashi, Takashi

AU - Komiyama, Shinichi

AU - Hirose, Takanori

PY - 2001

Y1 - 2001

N2 - Background. Ovarian ependymoma is an extremely unusual teratoma of the ovary with only eight cases previously reported in the literature worldwide. Case. A 26-year-old woman presented in 1992 with a sensation of abdominal fullness. The laparotomy revealed ovarian cancer (stage III), which proved to be an ependymoma pathologically. Three courses of the PVP regimen (cisplatin, vinblastine, peplomycin) and pelvic irradiation were administered postoperatively. Oral administration of etoposide (VP-16) was initiated after the residual tumor began to proliferate, and the tumor decreased in size and never regrew during etoposide administration for a total of 5 years and 8 months. The recurrent tumor was observed soon after the drug was discontinued. Conclusion. Oral administration of etoposide was effective in prolonging disease-free survival.

AB - Background. Ovarian ependymoma is an extremely unusual teratoma of the ovary with only eight cases previously reported in the literature worldwide. Case. A 26-year-old woman presented in 1992 with a sensation of abdominal fullness. The laparotomy revealed ovarian cancer (stage III), which proved to be an ependymoma pathologically. Three courses of the PVP regimen (cisplatin, vinblastine, peplomycin) and pelvic irradiation were administered postoperatively. Oral administration of etoposide (VP-16) was initiated after the residual tumor began to proliferate, and the tumor decreased in size and never regrew during etoposide administration for a total of 5 years and 8 months. The recurrent tumor was observed soon after the drug was discontinued. Conclusion. Oral administration of etoposide was effective in prolonging disease-free survival.

KW - Ependymoma

KW - Etoposide

KW - Ovarian neoplasma

KW - VP-16

UR - http://www.scopus.com/inward/record.url?scp=0034791119&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034791119&partnerID=8YFLogxK

U2 - 10.1006/gyno.2001.6343

DO - 10.1006/gyno.2001.6343

M3 - Article

VL - 83

SP - 149

EP - 152

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -